CIK 0001346830
- Non-accelerated filer
- Smaller reporting company
Tvardi Therapeutics, Inc.
Sign in to watch- Ticker
- TVRD
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- Phone
- +1 713-489-8654
- Business address
- 3 SUGAR CREEK CTR. BLVD., STE 525, SUGAR LAND, TX, 77478
- Former names
- Cara Therapeutics, Inc., Cara Therapeutics Inc
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-04-15 | Wirk Shaheen Director | Other acquisition | +263,164 | 263,164 | ||
| 2025-04-15 | Wirk Shaheen Director | Grant or award · Stock Option (right to buy) | +2,011 | 2,011 | ||
| 2025-04-15 | Shah Sujal Director | Grant or award · Stock Option (right to buy) | +10,394 | 10,394 | ||
| 2025-04-15 | Shah Sujal Director | Grant or award · Stock Option (right to buy) | +8,047 | 8,047 | ||
| 2025-04-15 | Larson Jeffrey Leroy SVP, Research & Development | Grant or award · Employee Stock Option (right to buy) | +16,764 | 16,764 | ||
| 2025-04-15 | Larson Jeffrey Leroy SVP, Research & Development | Grant or award · Employee Stock Option (right to buy) | +5,364 | 5,364 | ||
| 2025-04-15 | Conn Avi Daniel Chief Financial Officer | Grant or award · Employee Stock Option (right to buy) | +89,053 | 89,053 | ||
| 2025-04-15 | Alibhai Imran Nizamudin Chief Executive Officer | Grant or award · Employee Stock Option (right to buy) | +207,881 | 207,881 | ||
| 2025-04-15 | Alibhai Imran Nizamudin Chief Executive Officer | Grant or award · Employee Stock Optyion (right to buy) | +2,011 | 2,011 | ||
| 2025-04-15 | Alibhai Imran Nizamudin Chief Executive Officer | Grant or award · Employee Stock Option (right to buy) | +160,940 | 160,940 | ||
| 2025-02-28 | Posner Christopher PRESIDENT AND CEO | Sale | −583 | $4.75 | $3K | 13,109 |
| 2025-02-28 | Terrillion Scott SEC'Y; CHIEF COMPLIANCE & G.C. | Sale | −163 | $4.76 | $776 | 7,190 |
| 2025-02-04 | Posner Christopher PRESIDENT AND CEO | Sale | −372 | $4.72 | $2K | 13,692 |
| 2024-11-04 | Posner Christopher PRESIDENT AND CEO | Sale | −3,668 | $0.29 | $1K | 168,768 |
| 2024-08-01 | Posner Christopher PRESIDENT AND CEO | Sale | −4,149 | $0.35 | $1K | 172,436 |
| 2024-06-04 | Boudreau Helen M Director | Grant or award | +150,647 | 150,647 | ||
| 2024-06-04 | Boudreau Helen M Director | Grant or award · Stock Option (Right to Buy) | +195,000 | 195,000 | ||
| 2024-06-04 | von Moltke Lisa Director | Grant or award | +150,647 | 183,009 | ||
| 2024-06-04 | von Moltke Lisa Director | Grant or award · Stock Option (Right to Buy) | +195,000 | 195,000 | ||
| 2024-06-04 | Ives Jeffrey L. Director | Grant or award | +150,647 | 198,485 |
Page 3 of 7 · 123 trades